{"id":"botulinum-toxin-a-150u","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"10-20","effect":"Neck pain"},{"rate":"5-10","effect":"Muscle weakness"},{"rate":"5-10","effect":"Injection site pain"},{"rate":"1-5","effect":"Flu-like symptoms"},{"rate":"1-5","effect":"Eyelid ptosis"},{"rate":"1-3","effect":"Diplopia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE (soluble N-ethylmaleimide-sensitive factor attachment receptor) proteins required for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.","oneSentence":"Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:47.944Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Strabismus"},{"name":"Chronic migraine"},{"name":"Hyperhidrosis"},{"name":"Spasticity"},{"name":"Facial wrinkles (cosmetic)"}]},"trialDetails":[{"nctId":"NCT06584240","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity","status":"COMPLETED","sponsor":"JHM BioPharma (Tonghua) Co. , Ltd.","startDate":"2024-09-14","conditions":"Upper Limb Spasticity","enrollment":84},{"nctId":"NCT03199534","phase":"PHASE4","title":"A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction","status":"COMPLETED","sponsor":"EvergreenHealth","startDate":"2017-05-25","conditions":"Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction","enrollment":20},{"nctId":"NCT00915525","phase":"PHASE3","title":"Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":829},{"nctId":"NCT03119948","phase":"PHASE2","title":"Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-12","conditions":"Hemiparesis After Stroke, Traumatic Brain Injury","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®","OnabotulinumtoxinA"],"phase":"marketed","status":"active","brandName":"Botulinum toxin A 150u","genericName":"Botulinum toxin A 150u","companyName":"EvergreenHealth","companyId":"evergreenhealth","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}